Gilead 'Rewriting' History To Save $2.5B IP Win, Justices Told
Law360 (January 4, 2021, 9:43 PM EST) -- A Merck & Co. unit is fighting against Gilead Sciences Inc.'s arguments that the Federal Circuit correctly wiped out a $2.54 billion patent verdict it won against Gilead, telling the U.S. Supreme Court that Gilead's characterization of the ruling "rewrites the Federal Circuit's jurisprudence."
In a Dec. 30 reply brief, Idenix Pharmaceuticals LLC said the Federal Circuit got it wrong when it set a categorical rule that "genus claims" that cover a large number of chemical compounds cannot be patented. The appeals court's ruling has "devastating consequences for fields like biotechnology and pharmaceuticals," it said.
But Gilead, in its response last...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!